[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Jul05310473John Biotechdruganalyst Biotechdruganalyst posts on X about $crbp, $mrus, $8bn, market cap the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1554147770352762887/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +488% - X Months XXXXXX +223% - X Year XXXXXX -XXXX% ### Mentions: X [#](/creator/twitter::1554147770352762887/posts_active)  - X Week XX -XX% - X Month XX +213% - X Months XXX +158% - X Year XXX -XX% ### Followers: XXX [#](/creator/twitter::1554147770352762887/followers)  - X Week XXX +1.70% - X Month XXX +11% - X Months XXX +31% - X Year XXX +50% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1554147770352762887/influencer_rank)  ### Social Influence [#](/creator/twitter::1554147770352762887/influence) --- **Social category influence** [finance](/list/finance) XXXXX% [stocks](/list/stocks) XXXX% **Social topic influence** [$crbp](/topic/$crbp) #3, [$mrus](/topic/$mrus) #12, [$8bn](/topic/$8bn) 11.11%, [market cap](/topic/market-cap) 11.11%, [$skye](/topic/$skye) 5.56%, [$nvo](/topic/$nvo) 5.56%, [weight loss](/topic/weight-loss) 5.56%, [nvo](/topic/nvo) 5.56%, [$200mm](/topic/$200mm) 5.56%, [$cadl](/topic/$cadl) XXXX% **Top accounts mentioned or mentioned by** [@hannibalspeaks](/creator/undefined) [@biotenic](/creator/undefined) [@pedro3236143411](/creator/undefined) [@aaronrosenblum5](/creator/undefined) [@paulpetertak](/creator/undefined) [@candeltx](/creator/undefined) [@bwalkerttaggg](/creator/undefined) [@jessebrodkin](/creator/undefined) [@biovalues](/creator/undefined) [@persimmonti](/creator/undefined) [@andreagtc](/creator/undefined) [@kingachillese](/creator/undefined) [@investseekers](/creator/undefined) [@rnaianalyst](/creator/undefined) [@bigpharmaguy](/creator/undefined) **Top assets mentioned** [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Novo-Nordisk (NVO)](/topic/$nvo) [Bitcoin Incognito (XBI)](/topic/$xbi) ### Top Social Posts [#](/creator/twitter::1554147770352762887/posts) --- Top posts by engagements in the last XX hours "@KingachillesE If $crbp nectin-4 ADC at ESMO25 is equal or better than $mrus peto data the stock could trade up to as high as XX% of $mrus $8bn valuation=$ XXX mm market cap=$65 per share . Definitely at least 2-3 bagger if data good" [X Link](https://x.com/Jul05310473John/status/1973425733252030593) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-01T16:32Z XXX followers, XXX engagements "@hannibalspeaks @Biotenic $crbp competitor $skye failed. $nvo Monlunabant induced potent weight loss but still plagued by neuropsych and surprisingly high rate of GI toxicity. $crbp is last man standing in CB1. We know CRB-913 will induce W/L and if safety profile is clean drug will be blockbuster" [X Link](https://x.com/Jul05310473John/status/1976981908467921127) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-11T12:03Z XXX followers, XXX engagements "@BioValues Not $crbp Nectin X ADC data at #ESMO25. If HNSCC data is equal or better than $mrus stock is going way higher a double or triple. Stock still way cheap at $200mm market cap" [X Link](https://x.com/Jul05310473John/status/1979131280961786069) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-17T10:24Z XXX followers, XXX engagements "@BWalkerTTAGGG @paulpetertak @CandelTx Bull crap on Trinity . Real truth is $CADL cant raise sufficient equity capital . In a binary debt is great if you win but there is a much higher probability of losing" [X Link](https://x.com/Jul05310473John/status/1978858831917490447) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-16T16:21Z XXX followers, XXX engagements "@RNAiAnalyst $xbi going much higher . Biotech bull market just getting started . Big pharma has huge LOE cliff . Many more M&As to come" [X Link](https://x.com/Jul05310473John/status/1979134255608336535) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-17T10:35Z XXX followers, XXX engagements "@bigpharmaguy @AaronRosenblum5 @BioValues I dont think so because the big prize and the reason $gmab paid $8bn is 1L. obviously much bigger TAM for 1L . Once Pete 1L is approved it wont be used in 2L. 2L is wide open for $crbp. Response rates in 2L for chemo pembro and centuximab only 10-20%. 2L TAM is $1.5bn+" [X Link](https://x.com/Jul05310473John/status/1979139193625362579) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-17T10:55Z XXX followers, XXX engagements "$crbp Nectin X ADC data at #ESMO25 -rapid enrollment for PH1 study-167 patients enrolled & XXX evaluable including XX HNSC pts. If HNSCC data is equal or better than $mrus stock will rock- XX% of MRUS 7bn t/o=$800mm=$65 stock price" [X Link](https://x.com/Jul05310473John/status/1978074353825718583) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-14T12:24Z XXX followers, XXX engagements "@AaronRosenblum5 @PersimmonTI Dude youre so biased they just started combo data and it makes sense to start in 2L to see what shakes our in 1L" [X Link](https://x.com/Jul05310473John/status/1980762075874971954) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-21T22:24Z XXX followers, XX engagements "@AaronRosenblum5 @PersimmonTI Maybe but maybe not they have money in the bank and much stronger institutional ownership and support than pyxs. Btw if PYXS succeeds it will be a real sleeper. I dont hear a buzz at all from the street or clinicians" [X Link](https://x.com/Jul05310473John/status/1980767149431091633) [@Jul05310473John](/creator/x/Jul05310473John) 2025-10-21T22:44Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Biotechdruganalyst posts on X about $crbp, $mrus, $8bn, market cap the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence finance XXXXX% stocks XXXX%
Social topic influence $crbp #3, $mrus #12, $8bn 11.11%, market cap 11.11%, $skye 5.56%, $nvo 5.56%, weight loss 5.56%, nvo 5.56%, $200mm 5.56%, $cadl XXXX%
Top accounts mentioned or mentioned by @hannibalspeaks @biotenic @pedro3236143411 @aaronrosenblum5 @paulpetertak @candeltx @bwalkerttaggg @jessebrodkin @biovalues @persimmonti @andreagtc @kingachillese @investseekers @rnaianalyst @bigpharmaguy
Top assets mentioned Merus N.V. Common Shares (MRUS) Novo-Nordisk (NVO) Bitcoin Incognito (XBI)
Top posts by engagements in the last XX hours
"@KingachillesE If $crbp nectin-4 ADC at ESMO25 is equal or better than $mrus peto data the stock could trade up to as high as XX% of $mrus $8bn valuation=$ XXX mm market cap=$65 per share . Definitely at least 2-3 bagger if data good"
X Link @Jul05310473John 2025-10-01T16:32Z XXX followers, XXX engagements
"@hannibalspeaks @Biotenic $crbp competitor $skye failed. $nvo Monlunabant induced potent weight loss but still plagued by neuropsych and surprisingly high rate of GI toxicity. $crbp is last man standing in CB1. We know CRB-913 will induce W/L and if safety profile is clean drug will be blockbuster"
X Link @Jul05310473John 2025-10-11T12:03Z XXX followers, XXX engagements
"@BioValues Not $crbp Nectin X ADC data at #ESMO25. If HNSCC data is equal or better than $mrus stock is going way higher a double or triple. Stock still way cheap at $200mm market cap"
X Link @Jul05310473John 2025-10-17T10:24Z XXX followers, XXX engagements
"@BWalkerTTAGGG @paulpetertak @CandelTx Bull crap on Trinity . Real truth is $CADL cant raise sufficient equity capital . In a binary debt is great if you win but there is a much higher probability of losing"
X Link @Jul05310473John 2025-10-16T16:21Z XXX followers, XXX engagements
"@RNAiAnalyst $xbi going much higher . Biotech bull market just getting started . Big pharma has huge LOE cliff . Many more M&As to come"
X Link @Jul05310473John 2025-10-17T10:35Z XXX followers, XXX engagements
"@bigpharmaguy @AaronRosenblum5 @BioValues I dont think so because the big prize and the reason $gmab paid $8bn is 1L. obviously much bigger TAM for 1L . Once Pete 1L is approved it wont be used in 2L. 2L is wide open for $crbp. Response rates in 2L for chemo pembro and centuximab only 10-20%. 2L TAM is $1.5bn+"
X Link @Jul05310473John 2025-10-17T10:55Z XXX followers, XXX engagements
"$crbp Nectin X ADC data at #ESMO25 -rapid enrollment for PH1 study-167 patients enrolled & XXX evaluable including XX HNSC pts. If HNSCC data is equal or better than $mrus stock will rock- XX% of MRUS 7bn t/o=$800mm=$65 stock price"
X Link @Jul05310473John 2025-10-14T12:24Z XXX followers, XXX engagements
"@AaronRosenblum5 @PersimmonTI Dude youre so biased they just started combo data and it makes sense to start in 2L to see what shakes our in 1L"
X Link @Jul05310473John 2025-10-21T22:24Z XXX followers, XX engagements
"@AaronRosenblum5 @PersimmonTI Maybe but maybe not they have money in the bank and much stronger institutional ownership and support than pyxs. Btw if PYXS succeeds it will be a real sleeper. I dont hear a buzz at all from the street or clinicians"
X Link @Jul05310473John 2025-10-21T22:44Z XXX followers, XX engagements
/creator/twitter::Jul05310473John